Today: 20 May 2026
Browse Category

NYSE:TMO 8 December 2025 - 9 January 2026

Thermo Fisher stock slips again after the bell — here’s what traders are watching next for TMO

Thermo Fisher stock slips again after the bell — here’s what traders are watching next for TMO

Thermo Fisher shares fell 1.7% to $606.50 Thursday, extending losses after reaching a 52-week high of $628.08 earlier in the week. Trading volume topped 3 million shares, nearly double the average. The company will present at the J.P. Morgan Healthcare Conference on Jan. 13 and report earnings Jan. 29. Investors await updates on the $8.9 billion Clario acquisition, expected to close by mid-2026.
9 January 2026
··
Thermo Fisher stock cools after 52-week high as TD Cowen lifts target ahead of earnings

Thermo Fisher stock cools after 52-week high as TD Cowen lifts target ahead of earnings

Thermo Fisher shares slipped 0.2% to $619.19 in afternoon trading Wednesday after hitting a 52-week high Tuesday. TD Cowen raised its price target to $696 and kept a “buy” rating. Investors await CEO Marc Casper’s Jan. 13 conference appearance and Jan. 29 earnings for demand signals. Director Karen S. Lynch received 53.93 phantom stock units, according to a recent Form 4 filing.
7 January 2026
··
Thermo Fisher Scientific stock hits a 52-week high as Evercore lifts target and obesity registry launch draws focus

Thermo Fisher Scientific stock hits a 52-week high as Evercore lifts target and obesity registry launch draws focus

Thermo Fisher Scientific (TMO) closed up 1.6% at $620.72, a new 52-week high, before trading flat after hours. Evercore ISI raised its price target to $650, maintaining an Outperform rating. The company announced first patient enrollment in its PPD CorEvitas Obesity Registry. CEO Marc Casper will speak at the JPMorgan Healthcare Conference on Jan. 13, with earnings due Jan. 29.
7 January 2026
·
Thermo Fisher Scientific stock jumps as Evercore lifts target, with earnings in focus

Thermo Fisher Scientific stock jumps as Evercore lifts target, with earnings in focus

Thermo Fisher Scientific shares climbed 2.4% to $606.63 after Evercore ISI raised its price target to $650 and reaffirmed an “outperform” rating. The stock traded between $590 and $608.29 on volume of 1.6 million shares. Peers Danaher, Agilent, and Illumina also advanced. Investors await Thermo Fisher’s fourth-quarter results on Jan. 29 and updates on its planned $9.4 billion Clario acquisition.
5 January 2026
···
Thermo Fisher stock closes higher near 52-week high as January data, earnings loom

Thermo Fisher stock closes higher near 52-week high as January data, earnings loom

Thermo Fisher Scientific shares rose 2.25% to $592.51 Friday, closing about 3% below their 52-week high. The company will report Q4 and full-year results before the market opens on Jan. 29. Investors are watching for the ISM manufacturing report on Jan. 5 and U.S. jobs data on Jan. 9. Thermo Fisher’s $9.4 billion Clario deal is expected to close in early 2026.
4 January 2026
··
Thermo Fisher Scientific (TMO) Stock: Key News, Analyst Forecasts, and Catalysts to Watch Before the Market Opens on Dec. 26, 2025

Thermo Fisher Scientific (TMO) Stock: Key News, Analyst Forecasts, and Catalysts to Watch Before the Market Opens on Dec. 26, 2025

Thermo Fisher Scientific last traded near $579 in a holiday-shortened Dec. 24 session, giving the company a market cap of about $221 billion. Shares approach their 52-week high as investors watch for the closing of a planned $9.4 billion Clario acquisition, which could add $0.45 per share to adjusted earnings in its first year. U.S. markets reopen Dec. 26 after the Christmas break.
26 December 2025
·
Thermo Fisher Scientific Inc. (TMO) Stock Outlook: Latest News, Analyst Forecasts, and Key 2026 Catalysts (Dec. 25, 2025)

Thermo Fisher Scientific Inc. (TMO) Stock Outlook: Latest News, Analyst Forecasts, and Key 2026 Catalysts (Dec. 25, 2025)

Thermo Fisher Scientific shares last traded in the high-$570s on December 24, with short interest down to 5.10 million shares, or 1.35% of float. New SEC filings show Hunter Perkins Capital Management and DAVENPORT & Co LLC increased their stakes in Q3. Analyst consensus lists a “Moderate Buy” with a $616.60 average 12-month target. U.S. markets are closed for Christmas Day.
25 December 2025
·
Thermo Fisher Scientific Stock (TMO) News Today: What’s Driving Shares, Analyst Forecasts, and Key Catalysts on Dec. 19, 2025

Thermo Fisher Scientific Stock (TMO) News Today: What’s Driving Shares, Analyst Forecasts, and Key Catalysts on Dec. 19, 2025

Thermo Fisher Scientific shares rose 1.27% to $569.54 Friday after the company announced enrollment of the first patient in its PPD CorEvitas Alzheimer’s Disease Registry. The initiative aims to collect global real-world data on Alzheimer’s therapies. Thermo Fisher also opened a new collaboration center for life sciences startups in Philadelphia. Market cap stood near $218 billion.
19 December 2025
··
Thermo Fisher Scientific Stock (TMO) After Hours: Key News, Analyst Forecasts, and What to Watch Before the Market Opens on Dec. 19, 2025

Thermo Fisher Scientific Stock (TMO) After Hours: Key News, Analyst Forecasts, and What to Watch Before the Market Opens on Dec. 19, 2025

Thermo Fisher Scientific (TMO) closed at $562.39 on December 18, down 0.03%, despite a broad market rally. Shares traded between $554.53 and $569.41 during the session, with about 2.24 million shares changing hands. After hours, the stock remained steady near $562.40. The company announced enrollment of the first patient in its new Alzheimer’s Disease Registry.
19 December 2025
·
Thermo Fisher Scientific (TMO) Stock Today: Alzheimer’s Registry Launch, Analyst Price Targets, and 2026 Catalysts (Dec. 18, 2025)

Thermo Fisher Scientific (TMO) Stock Today: Alzheimer’s Registry Launch, Analyst Price Targets, and 2026 Catalysts (Dec. 18, 2025)

Thermo Fisher Scientific said Thursday it enrolled the first patient in its new PPD CorEvitas Alzheimer’s Disease Registry, aimed at collecting real-world evidence on neurodegenerative care. Shares traded near $561 in the afternoon, down slightly after a 1.33% drop Wednesday. The registry will track long-term safety and effectiveness of Alzheimer’s treatments, including MRI-based monitoring of drug side effects.
18 December 2025
··
Thermo Fisher Scientific (TMO) Stock: Latest Price, Today’s Institutional Moves, and Wall Street Forecasts on Dec. 17, 2025

Thermo Fisher Scientific (TMO) Stock: Latest Price, Today’s Institutional Moves, and Wall Street Forecasts on Dec. 17, 2025

Thermo Fisher Scientific shares fell 0.8% to $565.62 Wednesday as institutional filings and analyst upgrades drove trading. Assenagon Asset Management reported a large purchase, while Union Bancaire Privée cut its stake by 30.6%. About 953,000 shares changed hands intraday. The Health Care Select Sector SPDR ETF was flat, indicating stock-specific moves.
17 December 2025
Thermo Fisher Scientific (TMO) Stock Today: KeyBanc Sets $750 Target as Moody’s Upgrades Credit – December 8, 2025

Thermo Fisher Scientific (TMO) Stock Today: KeyBanc Sets $750 Target as Moody’s Upgrades Credit – December 8, 2025

Thermo Fisher Scientific shares traded near $567 late December 8, down about 1%, despite KeyBanc upgrading the stock to “Overweight” with a $750 target and Moody’s raising its credit rating. Hedge funds and insiders trimmed positions even as the company beat earnings, raised guidance, and continued acquisitions. Market cap stands around $215 billion.
8 December 2025
·
1 2 3 4

Stock Market Today

  • Celestica Inc: Over 20% Annualized Returns Anticipated Amid AI Hardware Surge
    May 19, 2026, 6:14 PM EDT. Celestica Inc (CLS) stands to gain from the growing demand for artificial intelligence (AI) hardware. This anticipated trend is expected to boost both the company's revenue (top-line) and profit margins, suggesting strong financial performance ahead. Analysts rate CLS stock as a Strong Buy, highlighting potential annualized returns exceeding 20%. Investors eyeing tech manufacturing and AI sectors may find Celestica's outlook particularly compelling amid evolving market dynamics.

Latest articles

JetBlue axes 12 routes; Fort Lauderdale responds

JetBlue axes 12 routes; Fort Lauderdale responds

20 May 2026
JetBlue will end all flights at Manchester-Boston Regional Airport on July 8 and cut nine other East Coast routes, shifting capacity to Fort Lauderdale. The move follows Spirit Airlines’ shutdown and increased competition in South Florida. JetBlue said Fort Lauderdale revenue per seat mile rose 5% in the first quarter. Manchester officials expressed disappointment, noting JetBlue made up no more than 5% of airport traffic.
Exxon, Chevron Say Oil Reserves Hit by Hormuz Choke, More Volatility Ahead

Exxon, Chevron Say Oil Reserves Hit by Hormuz Choke, More Volatility Ahead

20 May 2026
The U.S. shipped a record 9.9 million barrels from its emergency oil reserve last week, cutting stocks to 374 million barrels. Brent crude settled at $111.28 a barrel Tuesday after signs of progress in U.S.-Iran talks, but Exxon and Chevron warned the market has not fully absorbed the impact of the Strait of Hormuz closure. The IEA reported global oil inventories fell by 246 million barrels in March and April.
Toll Brothers Shares Jump on Earnings Beat, But There’s a Catch for Housing Bulls

Toll Brothers Shares Jump on Earnings Beat, But There’s a Catch for Housing Bulls

20 May 2026
Toll Brothers shares rose 2.7% to $127.50 in after-hours trading after quarterly profit and revenue topped Wall Street forecasts. Fiscal Q2 net income fell to $260.6 million from $352.4 million a year earlier, while home sales revenue dropped to $2.51 billion. The company raised its full-year delivery and pricing guidance despite high mortgage rates and softer industry sentiment.
Go toTop